The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...

Your doctor may have prescribed it for another reason. Cyclosporin Sandoz is only available with a doctor's prescription. It is not addictive. Do not take Cyclosporin Sandoz if you have ever had ...

This strategy enables Pfizer to maintain a strong foothold in the generic drug market while also protecting its revenue ...

Along with the $350 million upfront fee Sandoz is also pledging $150 million tied to sales performance in the deal, which excludes some rights to the drug in some markets including the US ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

South Korean pharmaceutical and biotechnology companies are on edge as U.S. President Donald Trump signals the introduction ...

Our latest report analyzes the US generic drug landscape, including an industry overview, historical data, deep dives into generic leaders—such as Teva, Sandoz, and Viatris—and more.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

RBC Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). Sandoz Group AG ...

The US OTC drugs market thrives, driven by increasing self-medication trends, diverse product offerings, and growing health ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.